In Brief: Sandoz
Sandoz: Proposes May 23 to acquire remaining shares of SyStemix for $17 per share, a 54.5% premium over SyStemix' closing price of $11. Sandoz already owns 73% of outstanding shares of Palo Alto-based SyStemix, which develops hematopoietic stem cell therapies for cancer, AIDS and genetic diseases. Sandoz purchased 60% of Systemix in December 1991 at prices ranging between $56 and $70 per share, double the market price...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth